Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

om non-clinical studies demonstrates that SNS-595 and cytarabine act synergistically to ablate bone marrow in experimental models while sparing normal hematopoietic recovery. Sunesis plans to initiate a Phase 1b clinical trial of SNS-595 in combination with cytarabine in patients with advanced acute leukemias in the third quarter of this year.

Non-clinical Results Compare CDK-Inhibitor SNS-032 to Flavopirodol

In a second presentation, Sunesis reported the results of studies evaluating its cyclin-dependent kinase (CDK)-inhibitor, SNS-032, which demonstrated that SNS-032 has greater selectivity and cellular potency to other CDK-targeting agents, such as flavopiridol and seliciclib. SNS-032 was analyzed against flavopiridol in a cancer cell line in bovine and human serum to assess mechanism of action and target modulation. SNS-032 was observed to be a more potent inhibitor of CDK9 and to possess greater pro-apoptotic activity than flavopiridol in human serum. In addition, mechanism-based, dose-dependent target modulation indicating CDK7 and CDK9 inhibition, as well as down-modulation of the survival signaling protein Mcl-1, was observed in peripheral blood cells obtained from patients treated with SNS-032 in a Phase 1 solid tumor clinical trial. These data further differentiate SNS-032 from flavopiridol.

"Results from these studies distinguish SNS-032 from other CDK inhibitors being tested in the clinic. Data presented on SNS-032 from comparative studies show this promising product candidate is hitting its molecular targets, including Mcl-1, in peripheral mononuclear cells taken from patients undergoing treatment in a dose-dependent fashion," said Dr. Adelman. "Our observations relating to SNS-032's mechanism support the ongoing Phase 1 clinical trial of SNS-032 in B-cell malignancies. This Phase 1 trial is designed to test our hypothesis that targeted inhibition of survival signaling in hematologic diseases will result in meaningful clinical benef
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Inc. (Nasdaq: BDSI ) will host a webcast ... AM Eastern Time to provide a business update which will ... of opioid dependence and an update on the development program ... addition, the webcast will include an update on the ONSOLIS ...
... Sheets: MDBX ) ( www.thedispensingsolution.com ) released ... systems, and the unit,s ability to better regulate and ... According to a recent report from the ... to the emergency room (ER) by nursing facility residents ...
Cached Medicine Technology:BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time 2BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time 3MedBox Medication Dispensing: Reducing Preventable ER Trips Through Better Medication Management 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... email management with its unique Netmail Platform, today ... World Partner Conference (WPC), which will be held ... July 13-17, 2014. During the show, Netmail will ... email management solution that consolidates email security, archiving, ...
(Date:7/10/2014)... 2014 The Capital Institute for Neurosciences ... first procedure in a clinical trial that delivers chemotherapy ... leg. , During the procedure, done at Capital Health ... neurosurgeon, threaded a tiny catheter through the patient’s femoral ... neck and into the brain. Once the catheter reached ...
(Date:7/10/2014)... 2014 Ticketability.com has a wide array of ... McCartney tickets for San Diego are being added to the ... 1976, and the newly added September 28 show is drawing ... Click Here to view the selection of discounted seats ... will become available to the general public on July 18 ...
(Date:7/10/2014)... July 11, 2014 According to ... Market by Platforms (Land, Airborne, Naval), Application (Software ... & by Geography (North America, Asia-Pacific, Europe, the ... (2014-2019)", published by MarketsandMarkets, the market is estimated ... expected to register a CAGR of 5.56% to ...
(Date:7/10/2014)... 2014 A Forever Recovery , ... clients off to a great start and gives them ... has launched a new Eating Disorders section of its ... highlights:, , Different types of eating ... Mental Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, and ...
Breaking Medicine News(10 mins):Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2
... designed to selectively weaken specific muscles may provide an ... attractive alternative treatment for frown lines, ... BFRM ) announced that it has acquired substantially ... Cosmetic Intervention,Inc. (ACI) and associated technology rights for $12 ...
... SpaBrite Teeth,Whitening System(TM) has introduced an FDA cleared ... the look of discolored teeth. The company,created the ... natural addition to the spa experience. Now the ... without compromising the effectiveness,of the treatment., The ...
... issued today by SEIU United Healthcare Workers-West:, In ... SEIU have launched a campaign, in the face of ... The most recent act of retaliation is their announcement ... board members created the,education fund in question in full ...
... YORK, April 29 It,s "Cover the ... attention on the nearly 47 million,Americans who ... this report from Pfizer (NYSE: PFE ... can access video, audio, text, graphics and,photos ...
... PITTSBURGH, April 29 Mylan Inc. (NYSE: ... Michael J. Monroe as senior vice,president - ... of the company,s senior,leadership team. In this ... and employee communications; corporate,branding/marketing; corporate media relations; ...
... or more of blood can be life-threatening , , ... that thicken the blood are highly effective in ... University of California, San Diego, bioengineering researchers. , ... standard emergency treatment for patients with severe bleeding. ...
Cached Medicine News:Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 2Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 3Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 4Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 5Health News:Beautiful Teeth Not Just for the Dentist's Office Anymore / SpaBrite Teeth Whitening System(TM) Introduces Innovative, New Teeth Whitening Experience To Spas 2Health News:Statement by UHW President Sal Rosselli on SEIU Threat to Sue UHW Leaders 2Health News:Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs 2Health News:Viscosity Enhancers Curb Bleeding Complications 2
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... and Needle is specially designed to help ... quality, reliable core sample. All needles are ... and polished surfaces for smooth entry and ... and needle sizes assures an ideal match ...
... is designed to bring efficiency and quality ... combines the superior technology of fluorescent flow ... Continuous sampling or batch processing are ... sample processing in high volume laboratories. ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: